Skip to main content

Table 4 Evaluation of tumor response after treatment in the two groups

From: Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study

 

Group

Chi-Square Tests(p-value)

TACE + Sunitinib group(N = 47)

Sunitinib group(N = 51)

Pearson Chi-Square

Fisher’s Exact Test

Tumor response

CR

Count(%)

4(8.5%)

0(0%)

0.017

 

PR

Count(%)

27(57.5%)

20(39.2%)

SD

Count(%)

9(19.1%)

14(27.5%)

PD

Count(%)

7(14.9%)

17(33.3%)

ORR

 

Count(%)

31(66.0%)

20(39.2%)

 

0.009

DCR

 

Count(%)

40(85.1%)

34(66.7%)

 

0.038

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us